z-logo
open-access-imgOpen Access
Antibiotic resistance of Staphylococcus aureus in children with atopic dermatitis in 2002-2004 versus 2007-2009 years
Author(s) -
М С Тренева,
А Н Пампура,
V R Voronina,
Z V Zaporozhtseva
Publication year - 2012
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja699
Subject(s) - staphylococcus aureus , medicine , cefuroxime , antibiotics , ciprofloxacin , penicillin , ampicillin , erythromycin , ceftriaxone , atopic dermatitis , microbiology and biotechnology , dermatology , biology , bacteria , genetics
Background. Staphylococus aureus (S. aureus) colonization is revealed in 80-84% of patients with atopic dermatitis (AD). There are no results on S. aureus susceptibility to antibiotics in children with AD within the period 2002-2004 to 2007-2009 years. Methods. S. aureus susceptibility to antibiotics was evaluated in 62 children with AD in 2002-2004 years and in 199 children in 2007-2009 years. S. aureus susceptibility and resistance to antibiotics were evaluated as frequencies (q) and their 95% confidential intervals (CI 95%) with MS «Excell». results. S. aureus antibiotic susceptibility in AD children is increased to ciprofloxacin since 2002-2004 to 2007-2009 [0,54 (0,42..0,67) /0,85 (0,80..0,91)] and is not changed to ceftriaxone [0,57 (0,44..0,70) /0,64 (0,57..0,71)], oxacillin [0,75 (0,64..0,86)/0,71 (0,64..0,78)] and cefuroxime [0,61 (0,49..0,74)/0,58 (0,36..0,80)]. Erythromycin susceptibility of S. aureus is 7 times reduced [0,71 (0,60..0,82)/0,10 (0,06..0,14)]; chloramphenicol susceptibility is 2 times reduced [0,79 (0,69..0,90)/0,33 (0,09..0,57)]. There is a decline of S. aureus antibiotic susceptibility to penicillin, ampicillin, linkomycin. Conclusion. Ceftriaxone may be the antibiotic of choice in children with severe infected AD. Oxacillin and cefuroxime should be recommended as an alternative choice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here